» Articles » PMID: 30992280

Engineering Multidimensional Evolutionary Forces to Combat Cancer

Overview
Journal Cancer Discov
Specialty Oncology
Date 2019 Apr 18
PMID 30992280
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

With advances in technology and bioinformatics, we are now positioned to view and manage cancer through an evolutionary lens. This perspective is critical as our appreciation for the role of tumor heterogeneity, tumor immune compartment, and tumor microenvironment on cancer pathogenesis and evolution grows. Here, we explore recent knowledge on the evolutionary basis of cancer pathogenesis and progression, viewing tumors as multilineage, multicomponent organisms whose growth is regulated by subcomponent fitness relationships. We propose reconsidering some current tenets of the cancer management paradigm in order to take better advantage of crucial fitness relationships to improve outcomes of patients with cancer. SIGNIFICANCE: Tumor and tumor immune compartment and microenvironment heterogeneity, and their evolution, are critical disease features that affect treatment response. The impact and interplay of these components during treatment are viable targets to improve clinical response. In this article, we consider how tumor cells, the tumor immune compartment and microenvironment, and epigenetic factors interact and also evolve during treatment. We evaluate the convergence of these factors and suggest innovative treatment concepts that leverage evolutionary relationships to limit tumor growth and drug resistance.

Citing Articles

Pan-cancer analysis and single-cell analysis reveals FAM110B as a potential target for survival and immunotherapy.

Li Y, Li X, Wu B, Su S, Su Y, Guo L Front Mol Biosci. 2024; 11:1424104.

PMID: 39170745 PMC: 11335499. DOI: 10.3389/fmolb.2024.1424104.


Peripheral Blood CD8 T-Lymphocyte Immune Response in Benign and Subpopulations of Breast Cancer Patients.

Lenart M, Bober P, Marcin M, Tkacikova S, Kacirova M, Alexovic M Int J Mol Sci. 2024; 25(12).

PMID: 38928129 PMC: 11204132. DOI: 10.3390/ijms25126423.


Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation.

Xiao B, Li G, Gulizeba H, Liu H, Sima X, Zhou T J Transl Med. 2024; 22(1):442.

PMID: 38730286 PMC: 11084143. DOI: 10.1186/s12967-024-05242-3.


FAM family gene prediction model reveals heterogeneity, stemness and immune microenvironment of UCEC.

Chi H, Gao X, Xia Z, Yu W, Yin X, Pan Y Front Mol Biosci. 2023; 10:1200335.

PMID: 37275958 PMC: 10235772. DOI: 10.3389/fmolb.2023.1200335.


Towards precision oncology with patient-derived xenografts.

Zanella E, Grassi E, Trusolino L Nat Rev Clin Oncol. 2022; 19(11):719-732.

PMID: 36151307 DOI: 10.1038/s41571-022-00682-6.


References
1.
Campbell P, Yachida S, Mudie L, Stephens P, Pleasance E, Stebbings L . The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467(7319):1109-13. PMC: 3137369. DOI: 10.1038/nature09460. View

2.
Hensen E, Bayley J . Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Fam Cancer. 2010; 10(2):355-63. PMC: 3100491. DOI: 10.1007/s10689-010-9402-1. View

3.
Zeller C, Dai W, Steele N, Siddiq A, Walley A, Wilhelm-Benartzi C . Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012; 31(42):4567-76. DOI: 10.1038/onc.2011.611. View

4.
Kirk D, Szalay M, KAIGHN M . Modulation of growth of a human prostatic cancer cell line (PC-3) in agar culture by normal human lung fibroblasts. Cancer Res. 1981; 41(3):1100-3. View

5.
Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View